Department of Radiotherapy, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
PLoS One. 2014 Feb 20;9(2):e88823. doi: 10.1371/journal.pone.0088823. eCollection 2014.
Previous observational studies investigating the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and acute myeloid leukemia risk (AML) have yielded inconsistent results. The aim of this study is to derive a more precise estimation of the association between MTHFR (C677T and A1298C) polymorphisms and acute myeloid leukemia risk. PubMed and Embase databases were systematically searched to identify relevant studies from their inception to August 2013. Odds ratios (ORs) with 95% confidence intervals (CIs) were the metric of choice. Thirteen studies were selected for C677T polymorphism (1838 cases and 5318 controls) and 9 studies (1335 patients and 4295 controls) for A1298C polymorphism. Overall, pooled results showed that C677T polymorphism was not significant associated with AML risk(OR, 0.98-1.04; 95% CI, 0.86-0.92 to 1.09-1.25). Similar results were observed for the A1298C polymorphism and in subgroup analysis. All comparisons revealed no substantial heterogeneity nor did we detect evidence of publication bias. In summary, this meta-analysis provides evidence that MTHFR polymorphisms were not associated with AML risk. Further investigations are needed to offer better insight into the role of these polymorphisms in AML carcinogenesis.
先前的观察性研究调查了亚甲基四氢叶酸还原酶（MTHFR）多态性与急性髓细胞白血病风险（AML）之间的关联，但其结果并不一致。本研究旨在更准确地评估 MTHFR（C677T 和 A1298C）多态性与急性髓细胞白血病风险之间的关联。系统地检索了 PubMed 和 Embase 数据库，以从其建立之初到 2013 年 8 月，确定相关研究。选择比值比（ORs）及其 95%置信区间（CIs）作为指标。有 13 项研究用于 C677T 多态性（1838 例病例和 5318 例对照），9 项研究用于 A1298C 多态性（1335 例患者和 4295 例对照）。总的来说，汇总结果表明 C677T 多态性与 AML 风险无关（OR，0.98-1.04；95%CI，0.86-0.92 至 1.09-1.25）。A1298C 多态性也观察到了类似的结果，且在亚组分析中也是如此。所有比较均未显示出显著的异质性，也未发现发表偏倚的证据。总之，这项荟萃分析提供的证据表明，MTHFR 多态性与 AML 风险无关。需要进一步的研究来更好地了解这些多态性在 AML 致癌中的作用。
